TRD has been in an rising channel for 6 years. The high of Dec 16/Jan 17 touched the top of the channel and resulted in a pull back and consolidation of 18 months. Price has reacted to the channel and formed a rounded bottom/cup. Likely outcomes are to form a 'handle' for the cup, or for price to move straight up, targeting the upper channel boundary.
Prudent Drug Discovery Company
Low market cap (appox £13m at time of writing).
Issues shares very rarely (last placing nearly four years ago).
Has material interest in its work from larger partners (Pharmaxis).
Sold interest in LOXL2 programme for £5m to Pharmaxis in December.
Pharmaxis continues to fund and develop LOXL2 inhibitors and Synairgen retains interest ...